Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

被引：2

作者：

Kayser, Sabine ^{[1
,2
]}

Heitmann, Jonas S. ^{[3
]}

Doerfel, Daniela ^{[4
,5
,6
]}

Thol, Felicitas ^{[7
]}

Heuser, Michael ^{[7
]}

Maerklin, Melanie ^{[5
,6
]}

Mueller-Tidow, Carsten ^{[8
]}

Steiner, Martin ^{[9
]}

Grosse-Hovest, Ludger ^{[9
]}

Jung, Gundram ^{[10
]}

Schlenk, Richard F. ^{[11
,12
,13
]}

Salih, Helmut R. ^{[5
,6
,14
]}

机构：

[1] Univ Hosp Heidelberg, Heidelberg, Germany

[2] German Canc Res Ctr, Heidelberg, Germany

[3] Univ Tubingen, Dept Hematol Oncol & Immunol, Tubingen, Germany

[4] Eberhard Karls Univ Tubingen, Dept Hematol & Oncol, Tubingen, Germany

[5] German Canc Consortium DKTK, Clin Collaborat Unit Translat Immunol, Tubingen, Germany

[6] German Canc Res Ctr, Partner Site Tuebingen, Dept Internal Med 2, Tubingen, Germany

[7] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany

[8] Heidelberg Univ Hosp, Dept Internal Med 5, Heidelberg, Germany

[9] SYNIMMUNE GmbH, Tubingen, Germany

[10] Eberhard Karls Univ Tubingen, Dept Immunol, Tubingen, Germany

[11] German Canc Res Ctr, NCT Clin Trials Off, Heidelberg, Germany

[12] Natl Ctr Tumor Dis, Heidelberg, Germany

[13] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[14] Univ Hosp Tuebingen, Dept Internal Med 2, Tubingen, Germany

来源：

关键词：

D O I：

10.1182/blood-2019-125327

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3928

引用

页数：4